Torrent Pharmaceuticals is reducing its medical representative force by 400 positions as it integrates JB Chemicals & Pharmaceuticals. While this restructuring is expected to cause a temporary revenue slowdown for the next two to three quarters, management anticipates realizing merger synergies faster than initially planned.
Torrent Pharmaceuticals is streamlining its sales operations following the official merger with JB Chemicals & Pharmaceuticals, which received NCLT approval and became effective on July 8, 2026. As part of this integration, the company plans to reduce its combined medical representative (MR) force from 9,400 to approximately 9,000 by the end of the year. This workforce adjustment is part of a broader effort to consolidate divisions and unify sales teams after Torrent acquired a 48.8% controlling stake in JB Pharma in January 2026.
Impact on Sales and Revenue
Management has signaled that the integration of JB Pharma’s established brands, such as Cilacar and Metrogyl, into Torrent’s existing distribution network may lead to a temporary dip in revenue across certain territories. This transition phase, which involves training staff and realigning territories, is expected to persist for the next two to three quarters. According to Managing Director Aman Mehta, while the company remains committed to growing its base business, the current priority is ensuring a smooth brand transfer process, with historical data from previous acquisitions suggesting that such temporary disruptions are typical during large-scale integrations.
Financial Context and Restructuring Costs
Financial discipline remains a key monitorable as the company absorbs the costs associated with the merger. In the quarter ending June 2026, Torrent Pharma reported ₹21 crore in exceptional items, which included ₹2 crore in acquisition-related costs and a ₹19 crore write-off for inventory lost in a fire at a former JB Pharma warehouse. This follows a ₹19 crore severance charge recognized in the March quarter. On the positive side, the company noted that retention has improved significantly, with the attrition rate for the JB Pharma field force dropping to 16% in June 2026, compared to nearly 30% prior to the acquisition.
Strategic Outlook
Beyond domestic operations, Torrent is reviewing its international portfolio to potentially phase out lower-margin products. The management team expressed confidence that the financial benefits of the merger, or synergies, could be realized earlier than the original three-year timeline, given the progress made since the acquisition began in January. Investors may monitor the upcoming quarterly results to assess how effectively the company manages the transition and whether the anticipated revenue growth resumes once the restructuring stabilizes. The primary focus for the next two quarters will remain on the execution of these internal alignments rather than aggressive expansion.